Vanda Pharmaceuticals Inc. (VNDA)
VNDA moved a median of -0.22% 30 minutes after news, and -0.22% by the close. How VNDA actually reacts to news — the realized, point-in-time move the market made, measured across 363 labeled events over the last three years with zero look-ahead.
VNDA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 363 |
| 30-min | -0.22% | 44% | 363 |
| 60-min | 0.00% | 50% | 363 |
| to close | -0.22% | 46% | 363 |
| Middle 50% of VNDA reactions | -1.19% to +0.95% |
|---|---|
| Median reaction (30-min) | -0.22% |
| Measured reactions | 363 |
Half of all Vanda Pharmaceuticals Inc. news events land between -1.19% and +0.95% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How VNDA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 46 | -0.10% | 46% | -0.30% |
| Rating reiterations | 38 | +0.20% | 55% | 0.00% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how VNDA ranks against every other measured name →
That’s how VNDA usually reacts — get an email when it moves on news →Email me when VNDA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VNDA's baseline. Nothing else.
Recent VNDA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program | Press release | PR Newswire | +3.59% | — | |
| Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting | Press release | PR Newswire | -2.27% | -4.54% | |
| Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder | Press release | PR Newswire | -0.94% | -4.10% | |
| Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences | Press release | PR Newswire | +0.54% | -3.78% | |
| Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission | Press release | PR Newswire | -0.57% | +0.76% | |
| NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. | Press release | PR Newswire | -0.57% | +0.76% | |
| Form 10-Q Vanda Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.09% | +11.20% | |
| Form 8-K Vanda Pharmaceuticals For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -1.09% | +11.20% | |
| Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results | Press release | PR Newswire | -1.09% | +11.20% | |
| Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026 | Press release | PR Newswire | +0.59% | +1.97% | |
| Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe | Press release | PR Newswire | -0.32% | +2.06% | |
| NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment | Press release | PR Newswire | -1.73% | -5.87% | |
| Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit | Press release | PR Newswire | -1.63% | -2.44% | |
| Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S | Press release | PR Newswire | +0.97% | +2.81% | |
| Form 8-K Vanda Pharmaceuticals For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -0.57% | -2.78% | |
| Form S-8 Vanda Pharmaceuticals | SEC filing · Form S-8 | SEC EDGAR | -0.57% | -2.78% | |
| Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis | Press release | PR Newswire | +0.23% | +1.09% | |
| Form 10-Q Vanda Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.29% | -8.32% | |
| Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences | Press release | PR Newswire | -1.70% | -3.24% | |
| Form 8-K Vanda Pharmaceuticals For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -1.29% | -8.32% | |
| Form EFFECT Vanda Pharmaceuticals | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -0.80% | |
| Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results | Press release | PR Newswire | -1.29% | -8.32% | |
| Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years | Press release | PR Newswire | +3.06% | +5.00% | |
| Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years | Press release | PR Newswire | +3.06% | +5.00% | |
| Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 | Press release | PR Newswire | -0.71% | +0.71% | |
| Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence | Press release | PR Newswire | +0.66% | +2.62% | |
| Form ARS Vanda Pharmaceuticals For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.05% | +3.61% | |
| Form DEF 14A Vanda Pharmaceuticals For: Jun 04 | SEC filing · Form DEF | SEC EDGAR | +1.05% | +3.61% | |
| Form DEFA14A Vanda Pharmaceuticals | SEC filing · Form DEFA14A | SEC EDGAR | +1.05% | +3.61% | |
| Form 8-K Vanda Pharmaceuticals For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | +1.03% | -1.76% | |
| Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors | Press release | PR Newswire | +1.03% | -1.76% | |
| Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines | Press release | PR Newswire | -0.35% | +1.59% | |
| Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists | Press release | PR Newswire | -0.34% | +0.55% | |
| Form 8-K Vanda Pharmaceuticals For: Mar 29 | SEC filing · Form 8-K | SEC EDGAR | -1.23% | +0.43% | |
| Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods | Press release | PR Newswire | -0.76% | -17.11% | |
| Form 8-K Vanda Pharmaceuticals For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +0.64% | -0.21% | |
| Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years | Press release | PR Newswire | +0.63% | -1.63% | |
| Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference | Press release | PR Newswire | +0.47% | +4.70% | |
| Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis | Press release | PR Newswire | +4.12% | -2.47% | |
| Form 8-K Vanda Pharmaceuticals For: Feb 20 | SEC filing · Form 8-K | SEC EDGAR | +0.75% | +1.49% | |
| Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation | Press release | PR Newswire | +0.75% | +1.49% | |
| Form 8-K Vanda Pharmaceuticals For: Feb 18 | SEC filing · Form 8-K | SEC EDGAR | -1.66% | -4.32% | |
| Form 10-K Vanda Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.20% | -14.41% | |
| Form S-3 Vanda Pharmaceuticals | SEC filing · Form S-3 | SEC EDGAR | -4.20% | -14.41% | |
| Form 8-K Vanda Pharmaceuticals For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | -4.20% | -14.41% | |
| Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | PR Newswire | -4.20% | -14.41% | |
| Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 | Press release | PR Newswire | +0.93% | -3.60% | |
| Form 8-K Vanda Pharmaceuticals For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | +0.52% | -5.29% | |
| Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder | Press release | PR Newswire | +0.52% | -5.29% | |
| Form 8-K Vanda Pharmaceuticals For: Dec 30 | SEC filing · Form 8-K | SEC EDGAR | +2.69% | +3.40% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VNDA section they belong to.
Where else VNDA is measured.
VNDA earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Bio-Techne Corp (TECH) | 363 | -0.06% | 44% |
| Tenet Healthcare Corporation (THC) | 363 | +0.22% | 60% |
| Rezolute, Inc. - (NV) (RZLT) | 362 | -0.23% | 44% |
| Erytech Pharma S.A. - American Depositary Shares (ERYP) | 360 | 0.00% | 29% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Vanda Pharmaceuticals Inc.'s median reaction calculated?
Every labeled VNDA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 363 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of VNDA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VNDA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.